Tag:
Warner Chilcott
Latest Headlines
Latest Headlines
Warner Chilcott sues Watson to stop generic contraceptive
In a bit of drug family planning, Warner Chilcott ($WCRX) has sued Watson Pharmaceuticals ($WPI) to prevent it from putting out a generic version of its oral contraceptive Lo Loestrin Fe.
Warner Chilcott's Puerto Rico plant still beset by problems
Warner Chilcott hopes to get manufacturing issues resolved for one oral contraceptive before generic competition on another starts eating away at its earnings.
Warner Chilcott lowers outlook
Ireland's specialty drug maker Warner Chilcott is was looking at "strategic alternatives," buzz words for putting itself up for sale.
Analysts size up Warner Chilcott's merits for sale
Bloomberg dug into the numbers to find Warner Chilcott delivers some sweet free cash flow, about 10 times more than the median among other specialty drugmakers.
Interested shoppers prompt Warner to weigh sale options
Warner Chilcott is the latest drugmaker to stir up the M&A pot. The company is looking at its options, including a possible sale, Bloomberg reports.
FDA says 5 years of Warner Chilcott's Ovcon BC pills suspect
In what appears to be another pregnancy risk to women taking birth control pills, the FDA has sent a warning letter to Warner Chilcott ($WCRX) saying that for 5 years the potency of its Ovcon pills has been in question.
Will Warner Chilcott score with last-minute tablet change?
Here's a new twist on the old keep-generics-at-bay strategy. Warner Chilcott ( $WCRX ) has scored its Doryx acne tablet to make it easier to split into smaller doses--and it's arguing that the new
Court grants favorable decision to Warner Chilcott in Doryx dispute
A New Jersey court has granted a motion for preliminary injunction against Mylan ( $MYL ) preventing the company from launching a generic version of Doryx 150 mg before a decision is made in Warner
Warner Chilcott plots 500 job cuts in European revamp
In the wake of losing patent protection on top-selling Actonel, Warner Chilcott is restructuring its European operations and plans to cut 500 jobs in the process. Actonel accounted for 70 percent of
Warner Chilcott returns rights to Leo Pharma for $1B
Leo Pharma will reacquire the licensing rights to its topical psoriasis treatments from Warner Chilcott for about $1 billion, the two drugmakers announced today. The deal, which is expected to be
